QNCX — Quince Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662774 ·
Last close
$33.48
Market Cap
$34.05M
52W High
$35.41
52W Low
$15.10
ADV30
35,224
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,112,000 | 35,912,000 | 26,623,000 | 18,163,000 | 10,951,000 |
| Dec 2025 | 0 | — | -16,236,000 | -39,458,000 | 93,523,000 | 5,809,000 | 129,237,000 |
| Sep 2025 | 0 | — | -11,364,000 | -13,442,000 | 109,899,000 | 6,452,000 | 108,840,000 |
| Jun 2025 | 0 | — | -9,895,000 | -16,049,000 | 117,210,000 | 16,826,000 | 105,474,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,451,000
Investing CF
$24,329,000
Financing CF
$27,265,000
CapEx
$-352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-128.80
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-424,539,000
Inventory
—
Receivables
$6,557,000
ST Investments
$0
EBIT TTM
$-48,607,000
Pretax Income TTM
$-35,209,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -50,429,000 | -83,979,000 | 93,523,000 | 129,237,000 | — | -41,425,000 |
| Dec 2024 | 0 | -36,170,000 | -56,828,000 | 114,478,000 | 84,332,000 | — | -31,904,000 |
| Dec 2023 | 0 | -27,142,000 | -31,385,000 | 167,900,000 | 82,816,000 | — | -18,292,000 |
| Dec 2022 | 0 | -51,190,000 | -51,660,000 | 103,910,000 | 3,317,000 | — | -44,038,000 |
TTM Snapshot
Revenues TTM
$1,846,000
NetIncome TTM
$-16,500,000
OpCashFlow TTM
$0
Assets (Latest)
$114,478,000
Forward EPS
$-4.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ESLA | Estrella Immunopharma, Inc. | $31.97M | $0.74 | — |
| ALGS | Aligos Therapeutics, Inc. | $37.73M | $6.93 | — |
| SCLX | Scilex Holding Co | $39.82M | $5.66 | — |
| EVAX | Evaxion A/S | $28.36M | $3.40 | — |
| ELUT | ELUTIA INC. | $42.30M | $0.95 | — |
News headlines (Yahoo Finance, 1h cache)
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
2026-06-30 12:00 · Yahoo
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
2026-06-02 13:56 · Yahoo
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
2026-05-18 14:21 · Yahoo
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
2026-05-18 13:26 · Yahoo
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
2026-05-18 13:26 · Yahoo
As Acasti Pharma Advances FDA Orphan-Designated GTX-102 Oral Mucosal Spray, New Report Maps 7MM Ataxia-Telangiectasia Treatment Landscape
2026-08-14 08:05 · Yahoo
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
2026-08-14 12:00 · Yahoo
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
2026-02-02 12:19 · Yahoo
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
2026-01-30 14:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.